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Abstract
Background: The Affymetrix GeneChip® system is a commonly used platform for microarray analysis but the
technology is inherently expensive. Unfortunately, changes in experimental planning and execution, such as the
unavailability of previously anticipated samples or a shift in research focus, may render significant numbers of pre-
purchased GeneChip® microarrays unprocessed before their manufacturer’s expiration dates. Researchers and
microarray core facilities wonder whether expired microarrays are still useful for gene expression analysis. In
addition, it was not clear whether the two human reference RNA samples established by the MAQC project in
2005 still maintained their transcriptome integrity over a period of four years. Experiments were conducted to
answer these questions.
Results: Microarray data were generated in 2009 in three replicates for each of the two MAQC samples with either
expired Affymetrix U133A or unexpired U133Plus2 microarrays. These results were compared with data obtained in
2005 on the U133Plus2 microarray. The percentage of overlap between the lists of differentially expressed genes
(DEGs) from U133Plus2 microarray data generated in 2009 and in 2005 was 97.44%. While there was some degree
of fold change compression in the expired U133A microarrays, the percentage of overlap between the lists of
DEGs from the expired and unexpired microarrays was as high as 96.99%. Moreover, the microarray data generated
using the expired U133A microarrays in 2009 were highly concordant with microarray and TaqMan® data
generated by the MAQC project in 2005.
Conclusions: Our results demonstrated that microarray data generated using U133A microarrays, which were more
than four years past the manufacturer’s expiration date, were highly specific and consistent with those from
unexpired microarrays in identifying DEGs despite some appreciable fold change compression and decrease in
sensitivity. Our data also suggested that the MAQC reference RNA samples, stored at -80°C, were stable over a time
frame of at least four years.
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As a powerful tool in genomic research, microarray tech-
nology has been widely used for simultaneously monitor-
ing expression levels of tens of thousands of genes [1-3].
The Affymetrix GeneChip® s y s t e mi sac o m m o n l yu s e d
platform for microarray analysis but the technology is
inherently expensive. We noticed that unforeseeable
changes in experimental planning and execution, e.g., una-
vailability of previously anticipated samples or a shift in
research focus could render pre-purchased GeneChip®
microarrays unprocessed before their manufacturer’s
expiration dates. Therefore, it is important to know
whether the expired but expensive GeneChip® microarrays
are still useful and reliable in gene expression studies.
A critical goal in the application of microarray tech-
nology is to identify differentially expressed genes
(DEGs) between sample groups under different condi-
tions. However, several studies showed poor overlaps of
DEGs across different platforms or different laboratories
using the same sets of RNA samples [4-8], raising con-
cerns on the reliability of microarray technology [9-13]
and leading to the launch of the MicroArray Quality
Control (MAQC) project [14,15]. The MAQC project
systematically evaluated the reliability of microarray
technology by profiling two human reference RNA sam-
ples (A = Stratagene’s Universal Human Reference RNA;
B = Ambion’s Human Brain Reference RNA) in different
laboratories using different microarray and QPCR plat-
forms. The MAQC consortium proposed to use fold
change ranking combined with a non-stringent p-value
cutoff for DEG selection and the percentage of overlap-
ping genes (POG) for evaluation of the reproducibility
of DEGs between different experiments. Excellent inter-
laboratory and inter-platform reproducibility in terms of
DEG lists was observed in the MAQC project [15,16].
In the current study, we assessed the consistency
between gene expression data generated with expired
and unexpired Affymetrix microarrays using the same
batches of MAQC samples and a similar data analysis
approach as proposed by the MAQC project. Our
results showed good reproducibility in terms of DEG
lists between the expired and unexpired microarrays. At
the same time, we also observed a high level of reprodu-
cibility between DEG lists from data generated in 2005
and those newly generated in 2009 with the same type
of unexpired U133Plus2 microarrays, suggesting a good
degree of stability of the two MAQC reference RNA
samples stored at -80°C over a period of four years.
Results
Study design and data generation
We designed and conducted a comparative study to
answer the question whether gene expression data
generated with Affymetrix U133A microarrays, four
years past their expiration date, are useful and reliable.
Figure 1 depicts the overview of the study, the experi-
mental procedures, data used, and comparative analyses
applied. Two sources of data were used in this study:
gene expression data newly generated in 2009 specifi-
cally for this study and data generated by the MAQC
project in 2005.
The new gene expression data were generated with 12
microarrays (2 types of microarrays × 2 samples × 3
replicates) (Table 1). Three replicates for each of the
two MAQC samples (A and B) were profiled in 2009 by
using both the expired U133A microarrays (expired in
2004) and the unexpired U133Plus2 microarrays. In
addition, gene expression data generated with unexpired
U133Plus2 microarrays (AFX), other microarray plat-
forms, and TaqMan® assays by the MAQC project in
2005 were used as references to assess the stability of
the MAQC samples stored at -80°C for four years by
comparing new microarray data with those obtained
four years ago. The MAQC reference data also allowed
for further evaluation of the usefulness of the data gen-
erated with expired U133A microarrays.
It should be pointed out that in the current study the
observed differences between the expired and unexpired
Affymetrix microarrays were confounded with the use of
two different types of GeneChip® microarrays, U133A
(expired four years ago) and U133Plus2 (unexpired).
However, the probe design (probe length and sequence
identity) for these two types of GeneChip® microarrays
is identical and the consistency of data between the two
types of microarrays was demonstrated by the manufac-
turer (http://media.affymetrix.com/support/technical/
technotes/hgu133_p2_technote.pdf). Therefore, the
observed difference between expired U133A and unex-
pired U133Plus2 microarrays can be attributed mainly
to the expiration of the former.
Stability of the two MAQC samples over a period of four
years
The two MAQC human reference RNA samples, from
the same batches as used in the MAQC project in 2005
but stored at -80°C for over four years, were labeled and
hybridized in 2009 on expired U133A and unexpired
U133Plus2 microarrays. Before comparing data from the
expired and unexpired microarrays, it is necessary to
verify the stability of the MAQC samples through asses-
sing the consistency between gene expression data gen-
erated in 2005 and in 2009 using the same type of
unexpired Affymetrix U133Plus2 microarrays.
Figure 2 shows the correlation of log2 fold changes
observed in 2009 and in 2005 with unexpired
U133Plus2 microarrays. The correlations are shown in
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Page 2 of 13Figures 2a, 2b, and 2c for the 8,550 genes commonly
probed by multiple microarray platforms, the 7,069
genes with a p < 0.05 in either of the two data sets
(2009 and 2005), and the 5,880 genes with a p <0 . 0 5i n
both data sets, respectively. It can be seen from Figure 2
that most genes showed similar log2 fold changes.
Under the three gene selection scenarios (a, b, and c)
with increasing stringency, the overlap of DEGs between
2009 and 2005 was 91.37%, 97.44%, and 99.78%, respec-
tively, suggesting a reasonably high degree of stability of
the two MAQC samples over a period of four years.
Thirteen genes showed opposite regulation directional-
ities between the data sets generated in 2005 and in
2009 (Figure 2c). It should be pointed out that DEG
concordance is only a surrogate of sample stability and
more direct measurement of sample stability is war-
ranted in future studies.
Repeatability of intensity data among sample replicates
on expired microarrays
The probe-level raw intensity data were first summar-
ized and normalized with the RMA algorithm [17] and
then transformed to log2 scale. Figures 3a and 3b show
the correlation of the log2 gene expression intensities
for the 8,550 common genes between replicates on the
expired U133A and unexpired U133Plus2 microarrays,
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Figure 1 The workflow of study design and data analysis New gene expression data were generated in 2009 with expired U133A
microarrays and unexpired U133Plus2 microarrays using the same MAQC reference RNA samples and compared to the microarray and TaqMan®
gene expression data generated in 2005 by the MAQC project.
Table 1 New data generated for this study with Affymetrix GeneChip® microarrays
Type of microarrays Sample
1 Hybridization name Scaling factor Averaged correlation
2
A1 4.58
A A2 4.76 0.994
U133A (expired in 2004) A3 4.29
B1 4.40
B B2 4.46 0.995
B3 5.17
A1 2.64
A A2 2.95 0.998
U133Plus2 A3 2.72
B1 2.78
B B2 2.97 0.997
B3 2.97
1Sample A: Stratagene’s Universal Human Reference RNA; Sample B: Ambion’s Human Brain Reference RNA;
2Averaged Pearson correlation coefficient for pair-
wise log2 intensity comparison across the three replicates.
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Page 3 of 13respectively. For the expired U133A microarrays (Figure
3a), the replicates of the same sample showed a high
level of correlation similar to what was observed for the
unexpired U133Plus2 microarrays (Figure 3b). More
quantitatively, the average correlation coefficients of the
log2 intensities among the replicates of sample A were
0.994 and 0.998 for the expired and unexpired microar-
rays, respectively. For sample B, the corresponding aver-
age correlation coefficients were 0.995 and 0.997 from
the expired and unexpired microarrays, respectively
(Table 1). These results demonstrated a high level of
i n t r a - s a m p l er e p e a t a b i l i t yo fa b s o l u t eg e n ee x p r e s s i o n
data from expired U133A microarrays.
Comparison of log2 fold changes detected with expired
U133A and unexpired U133Plus2 microarrays
To address the issue of using expired microarrays, the log2
fold changes of data obtained with the expired U133A
microarrays and the unexpired U133Plus2 microarrays were
compared (Figure 4). The log2 fold changes for most genes
were consistent in the direction of regulation (down or up).
However, there was a slight fold change compression [18]
for the data obtained with the expired U133A microarrays.
That is, the magnitude of differential expression (fold
change) for the same gene measured from the expired
U133A microarrays (the X axis) was lower than that from
the unexpired U133Plus2 microarrays (the Y axis).
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Figure 2 Comparisons of the log2 fold changes detected in 2009 and in 2005 using the same type of U133Plus2 microarrays (a) all
8,550 common genes; (b) the 7,069 genes with p < 0.05 in either 2009 or 2005; and (c) the 5,880 genes with p < 0.05 in both 2009 and 2005.
Fold changes were generated by comparing sample B to sample A, i.e., B/A. The blue and green dots indicated the up- and down-regulated
genes, respectively. The red dots were the genes with reverse regulation directionalities in 2009 and in 2005. Under the three scenarios (a, b,
and c), the overlap of differentially expressed genes between 2009 and 2005 is 91.37%, 97.44%, and 99.78%, respectively, suggesting a high
degree of stability of the two MAQC reference RNA samples.
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Page 4 of 13The percentage of overlapping genes with the same
directional change in expression was 89.94% (7,690 out
of 8,550 common genes) when no p-value cutoff was
applied to either experiment (Figure 4a). The overlap
increased to 96.99% (6,629 out of 6,835 genes) when
genes were retained for comparison as long as a p <
0.05 criterion was met in either one of the two experi-
ments (Figure 4b), a fair scenario for comparing two
data sets. When the comparison was restricted to the
subset of 5,120 genes that were simultaneously detected
to be significantly differentially expressed (p < 0.05) in
both experiments, the overlap increased to 99.98%. That
is, only one gene showed opposite regulation direction-
alities between expired U133A microarrays and unex-
pired U133Plus2 microarrays. These results suggested
that the DEGs detected by the expired U133A microar-
rays were highly consistent with those by the unexpired
U133Plus2 microarrays.
Comparison between expired U133A microarrays with
multiple microarray platforms used in the MAQC project
Microarray data generated in 2005 with the same
MAQC samples from five platforms, Applied Biosystems
(ABI), Affymetrix U133Plus2 (AFX), Agilent (AG1), Illu-
mina (ILM), and GE Healthcare (GEH) by the MAQC
project [15] were used as references to further assess
the usefulness of the expired U133A microarrays. To
assess the concordance between two experiments, we
first used a p < 0.05 cutoff to eliminate genes separately
in each experiment and then rank-ordered the remain-
ing genes by log2 FCs. In one experiment, genes ranked
higher in either the up- or down-regulation direction
are selected as DEGs first. Figure 5 shows the relation-
ship between the POG and the number of selected
DEGs, wherein genes with smaller FCs are selected
when more genes are chosen as DEGs. The red line
represented the average POG between DEG lists of each
of the four reference microarray data sets in the MAQC
p r o j e c t( A B I ,A G 1 ,I L M ,a n dG E H )a n dt h er e f e r e n c e
Affymetrix U133Plus2 (AFX) data, all generated in 2005.
This reference line and its confidence limits can be used
to judge the statistical significance between any two
experiments, e.g., between expired U133A microarrays
and unexpired U133Plus2 microarrays.
The concordance between DEG lists selected from
expired U133A microarrays and unexpired U133Plus2
microarrays (2009 or 2005) were about 70% when the
number of selected DEGs was as few as 10. These POG
numbers increased to near 90% when more genes were
selected as differentially expressed. For the same num-
ber of DEGs, the POGs between expired U133A (2009)
and unexpired U133Plus2 (2009) microarrays, and
between expired U133A (2009) and the reference
U133Plus2 (AFX in 2005) microarrays were on the
upper confidence limit of the reference line. This means
that compared to data from the reference AFX microar-
rays (2005), the DEGs generated with expired U133A
microarrays (2009) are more consistent than those from
other unexpired, but different microarray platforms
(ABI, AG1, ILM, and GEH) in 2005. In addition, the
POG between the unexpired U133Plus2 (2009) and the
reference AFX microarrays (2005) was the highest,
again, suggesting that the MAQC samples were rela-
tively stable.
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Figure 3 Correlations of log2 intensities generated in 2009 among the replicates of samples A and B (a) expired U133A microarrays and
(b) unexpired U133Plus2 microarrays. Each scatterplot represents the comparison of log2 intensities of 8,550 common genes from two
hybridizations.
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Page 5 of 13Comparison between expired U133A microarrays and
TaqMan® assays
TaqMan® assays have been widely used in gene expres-
sion profiling and are generally considered as a good
reference for evaluating other gene expression techni-
ques. In this study, the TaqMan® gene expression data
generated by the MAQC project in 2005 using the same
MAQC samples [15,19] were used to further assess the
usefulness of the expired U133A microarrays based on
data from the 813 genes that were probed by both the
microarrays and TaqMan® assays. The DEG lists
obtained from expired U133A microarrays (2009), unex-
pired U133Plus2 microarrays (2009), and microarrays
from ABI, AFX, AG1, ILM, and GEH (2005) were sepa-
rately compared with those from the TaqMan® assays
performed in 2005 [19]. The mean POG of the DEG
lists between the TaqMan® assays and the microarray
platforms (ABI, AFX, AG1, ILM, and GEH) was shown
as a reference line (the red crosses in Figure 6). The
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Figure 4 Comparisons of log2 fold changes detected with expired U133A and unexpired U133Plus2 microarrays (a) all 8,550 common
genes; (b) the 6,835 genes with p < 0.05 in either expired U133A microarrays (2009) or unexpired U133Plus2 microarrays (2009); and (c) the
5,120 genes with p < 0.05 in both expired U133A (2009) and unexpired U133Plus2 (2009) microarrays. Fold changes were generated by
comparing sample B to sample A, i.e., B/A. The blue and green dots indicated the up- and down-regulated genes, respectively. The red dots
were the genes with reverse regulation directionalities. Under the three scenarios (a, b, and c), the overlap of differentially expressed genes
between expired U133A (2009) and unexpired U133Plus2 (2009) microarrays is 89.94%, 96.99%, and 99.98%, respectively, indicating a high degree
of consistency between differential gene expression data generated from expired U133A and unexpired U133Plus2 microarrays. Note that the
fold changes measured with expired U133A microarrays exhibited some degree of compression (i.e., with smaller absolute values) when
compared to those obtained with unexpired U133Plus2 microarrays.
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Page 6 of 13and the TaqMan® assays (pink diamonds) was close to
the reference line when the number of DEGs was as low
as 40 but was about 10% lower than the reference line
when all genes meeting the p < 0.05 criterion were
selected (a drop from ~77% to ~70%). In addition, the
POG between unexpired U133Plus2 microarrays (2009)
and TaqMan® assays (black squares) and the POG
between the AFX (2005) and TaqMan® assays (sky blue
triangles) were higher than, or at the same level as, the
reference line. That is, compared to unexpired microar-
rays, expired U133A microarrays exhibited a slightly
decreased ability to detect differential gene expression,
mainly due to the fold change compression that made
the rankings of genes with smaller fold changes more
variable.
Characteristics of gene expression data measured on
unexpired U133Plus2 and expired U133A microarrays
The lower sensitivity of the expired U133A microarrays
in detecting differential gene expression could be
explained by a decrease in microarray signal or an
increase in the scaling factor (Table 1). The average
scaling factor was 4.61 for the expired U133A microar-
rays and 2.83 for the unexpired U133Plus2 microarrays.
The higher scaling factor for the expired microarrays
indicates that compared to the unexpired microarrays,
the quality of hybridization signals from the expired
microarrays was somewhat compromised, leading to a
decrease in sensitivity.
Figure 7 shows the distributions of log2 intensities for
8,550 common genes when the MAQC samples were
analyzed with the expired U133A and the unexpired
U133Plus2 microarrays. Compared to the U133Plus2
microarrays, which showed a mean log2 intensity of 7.79
for sample A (Figure 7b) and 7.67 for sample B (Figure
7d), the expired U133A microarrays exhibited a signifi-
cant decrease in mean log2 intensity, i.e., 6.27 for sample
A (Figure 7a) and 6.29 for sample B (Figure 7c). The
standard deviations of log2 intensity for unexpired
U133Plus2 microarrays (2.32 for sample A and 2.30 for
Figure 5 Concordances of different microarrays in terms of percentage of overlapping genes (POG) The x-axis represents the number of
genes (2L) selected as differentially expressed, and the y-axis represents the overlap (%) of two gene lists selected from the two experiments
under comparison. All of the genes in the two compared experiments were first filtered with a p < 0.05 cutoff and then ranked by fold changes
in up- and down directions. Next, the top L genes with the largest fold changes were selected as differentially expressed from each direction
and the DEG list containing 2L genes from each experiment was used for cross-experiment comparisons. L was increased from one to the lower
number of genes in both regulation directions with a step of one. The red crosses represent the reference line, i.e., the mean POG of DEG lists in
four comparisons of microarray reference data groups in MAQC project: ABI, AG1, ILM, and GEH versus AFX. The dashed and dotted green and
blue markers showed the lower limit and the upper limit of the 95% confidence intervals, respectively, for the reference line.
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Page 7 of 13sample B) are also higher than those for expired U133A
microarrays (1.93 for sample A and 1.95 for sample B),
indicating a decrease in the ability of expired microar-
rays to distinguish differences of expression levels
among genes in the same sample. In addition, as shown
in Figure 8, there is a significant difference in the per-
centage of Present calls between unexpired U133Plus2
(73.6%) and expired U133A (64.5%) microarrays, also
suggesting a significant loss of detection signals for the
expired U133A microarrays.
Discussion
Many users of microarrays face time pressures to com-
plete their studies while staying within the expiration
dates on the microarrays. Moreover, it is important to
understand the stability of RNA samples after years of
storage. Our current study investigated the stability of
two MAQC human reference RNA samples and exam-
ined the reliability of expired Affymetrix U133A micro-
arrays in gene expression analyses. We compared the
gene expression data of expired and unexpired microar-
rays from three aspects: absolute expression intensities,
log2 fold changes, and the POG of DEG lists, using data
newly generated in 2009 with the same pair of reference
RNA samples used in 2005 by the MAQC project. In
addition, the gene expression data generated using dif-
ferent platforms (ABI, AFX, AG1, ILM, GEH, and Taq-
Man®)i n2 0 0 5b yt h eM A Q Cp r o j e c tw e r eu s e da s
references to evaluate the reliability of the expired
U133A microarrays and also to assess the stability of the
MAQC samples.
Based on the log2 fold changes, microarray data gener-
ated in 2009 were highly consistent (97.44%) with those
generated by the MAQC project in 2005 using exactly
t h es a m et y p eo fu n e x p i r e dA f f y m e t r i xU 1 3 3 P l u s 2
microarrays and with the same pair of RNA samples
t h a th a db e e ns t o r e da t- 8 0 ° Cf o ro v e rf o u ry e a r s( F i g -
ures 2 and 5). Moreover, when compared with the Taq-
Man® assay data generated by the MAQC project in
2005, the two sets of data (2009 and 2005) from unex-
pired U133Plus2 microarrays showed similar results
(Figure 6). Our comparative analyses indicated that the
microarray data generated in 2009 from the same pair
of MAQC RNA samples were reliable and that the RNA
samples used in this study were reasonably stable after a
period of at least four years. Therefore, it is a reasonable
strategy to use these samples for assessing the reliability
of the expired U133A microarrays.
Figure 6 Concordance between TaqMan® assays and microarray data in terms of percentage of overlapping genes (POG) The x-axis
represents the number of genes (2L) selected as differentially expressed, and the y-axis represents the overlap (%) of two gene lists selected
from the two experiments under comparison. See notes under Figure 5 for more information.
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genes identified from expired U133A microarrays as differ-
entially expressed were consistent in the direction of regu-
lation with those from unexpired U133Plus2 microarrays
when the comparison was restricted to those genes with p
< 0.05 in at least one experiment (Figure 4b). These results
suggested that the DEGs detected by the expired U133A
microarrays were highly compatible with those identified
by the unexpired U133Plus2 microarrays. Our compara-
tive analyses also showed that the DEG lists generated
with the expired U133A microarrays were more reprodu-
cible than those from other unexpired microarray plat-
forms (ABI, AG1, ILM, and GEH) in 2005 when
compared to the DEG lists from unexpired U133Plus2
microarrays in 2005 (AFX) and in 2009 (Figure 5). That is,
the level of concordance between expired and unexpired
Affymetrix microarrays is higher than the level of concor-
dance between unexpired Affymetrix microarrays and
microarrays from other different platforms.
T h eP O Go ft h eD E Gl i s t sf r o mt h ee x p i r e dU 1 3 3 A
microarrays and the TaqMan® assays was ~10% lower
than the average POG of the DEG lists between the
unexpired microarrays and TaqMan® assays (Figure 6).
The number of DEGs detected by the expired U133A
microarrays was lower than that by the unexpired
U133Plus2 microarrays and the magnitude of the differ-
ential gene expression (fold change) detected by expired
U133A microarrays was also lower.
Figure 7 Distribution of the log2 intensities of 8,550 common genes Sample A hybridized on expired U133A (a) and unexpired U133Plus2
(b) microarrays; Sample B hybridized on expired U133A (c) and unexpired U133Plus2 (d) microarrays. For each gene, the log2 intensities of the
three technical replicates were averaged. Based on microarray data generated in 2009.
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In this study, two human reference RNA samples, estab-
lished and used in the MAQC project four years ago,
were used to assess a) the stability of these reagents and
b) the reliability of data generated on Affymetrix’s
U133A microarrays expired four years ago. By compar-
ing the detected log2 fold changes and the POG between
the DEG lists from unexpired Affymetrix U133Plus2
microarrays in 2005 and in 2009, we first demonstrated
that the reference RNA samples were relatively stable
and in reasonably good quality. Comparative analyses
showed a reasonable level of consistency in DEG lists
between the expired and unexpired microarrays. Com-
parison between DEG lists from expired U133A micro-
arrays and TaqMan® assays showed a decrease in
sensitivity of expired U133A microarrays by approxi-
mately 10%. In addition to possible sample-related rea-
sons, the increase of scaling factors, the shrinkage of the
distribution of detected raw intensities, and the lower
percentage of Present calls indicate a decrease in detec-
tion sensitivity for the expired microarrays. Our results
suggested that the Affymetrix U133A microarrays
expired four years ago generated useful, but somewhat
less sensitive, data for identifying genes differentially
expressed. It is warranted to continue to monitor the
stability and integrity of the MAQC reference RNA
samples because of their wide applications by the gene
expression community.
Methods
Microarray data generated in 2009 on U133Plus2 and
expired U133A microarrays
The two reference RNA samples A (Stratagene’s Universal
Human Reference RNA) and B (Ambion’s Human Brain
Reference RNA), which were established and extensively
profiled in the MAQC project in 2005 [15], were pur-
chased in 2009 from Agilent and Life Technologies,
respectively, to generate new microarray gene expression
data specifically for this study. The samples had been
stored under -80°C at their respective vendor’ freezer since
2005, and were shipped with dry ice from the vendors to
the microarray laboratory of Dr. Charles Wang at UCLA.
The same batches of the two samples as those used in the
MAQC project in 2005 were used in this study. Upon
Figure 8 Percentage of Present calls based on 8,550 common genes There is a significant difference in the percentage of Present calls
between unexpired U133Plus2 microarrays (73.6%) and expired U133A microarrays (64.5%). Based on microarray data generated in 2009.
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evaluated and confirmed their quality using the RNA 6000
LabChip and Agilent 2100 Bioanalyzer. The RNA Integrity
Number (RIN) for each sample was around 8.0. Biotiny-
lated cRNA samples were prepared according to the stan-
dard Affymetrix GeneChip® protocol. One µg of total
RNA from each sample, along with poly A spikes (labeling
control), were converted to double-stranded cDNA with
GeneChip® One-Cycle cDNA Synthesis Kit (Affymetrix,
Santa Clara, CA). After second-strand synthesis, the
cDNA was purified with the GeneChip® Sample Cleanup
Module (Affymetrix). The resulting double-stranded DNA
was then used to generate multiple copies of biotinylated
cRNA by in vitro transcription with the GeneChip® 3’-
Amplification Reagent Kit for IVT Labeling (Affymetrix).
The A260/A280 ratio and yield of each of the cRNAs were
recorded. For each sample, 10 µg of biotinylated cRNA
spiked with bioB, bioC, bioD and cre (Hybridization Con-
trol) was hybridized to a GeneChip® microarray for 16
hours at 45°C. Following hybridization, all microarrays
were washed and stained in an Affymetrix GeneChip®
Fluidics Station. Stained microarrays were scanned with
an Affymetrix GeneChip® Scanner 3000. Quality checks
and data analyses were carried out using Affymetrix Gene-
Chip® Operating Software (GCOS) and Quality Reporter.
Each of the two samples was processed in triplicate, start-
ing from independent labeling reactions with a new ali-
quot of the reference sample from the same tube, a) on
Affymetrix Human Genome U133A microarrays that were
four years ago past the manufacturer’s expiration dates
and b) on unexpired Human Genome U133Plus2 microar-
rays. The expired U133A microarrays were stored in a
refrigerator at 4°C, as recommended by the manufacturer.
In total, gene expression data were collected from 12 (2
types of microarrays × 2 samples × 3 replicates) microar-
rays. The comparisons among the microarrays were based
on 8,550 common genes, which represented the intersec-
tion of the 12,091 genes commonly probed by the micro-
array platforms used in the MAQC project [15] and the
genes probed by the U133A microarray platform used in
this study. It should be pointed out that from 2005 to
2009 Affymetrix implemented some changes such as the
sources of labeling kits into its GeneChip® product pipe-
line. Consequently, comparing gene expression data from
the same sample in 2005 and 2009 at the intensity level is
not meaningful, because it has been demonstrated that
intensity data are highly dependent on the labeling proto-
cols among many other factors.
Microarray and TaqMan® data generated by the MAQC
project in 2005
The gene expression data generated from the two sam-
ples by the MAQC project with five commercial
microarray platforms, Applied Biosystems (ABI),
Affymetrix (AFX), Agilent (AG1), Illumina (ILM), and
GE Healthcare (GEH), and with the TaqMan® (TAQ)
assays were obtained from the MAQC project
(GSE5350) and used in this study as references for
comparison. For fair comparisons, the first three
replicates reported by the MAQC project from each
platform’s first test site were used in this study. For
cross-platform comparison, the MAQC consortium
mapped all the probe sequences of the five high-den-
sity microarray platforms to the RefSeq human mRNA
database [20] and selected 12,091 common Entrez
genes that were uniquely matched by 12,091 probes/
probesets on each of the five microarray platforms,
resulting in a “one-probe-to-one-gene” cross-platform
mapping table with 12,091 genes and the probe/probe-
set identifiers from multiple microarray platforms and
TaqMan® assays (http://www.nature.com/nbt/journal/
v24/n9/extref/nbt1239-S5.txt) [15]. The probeset IDs
from the U133A platform used in this study were
mapped to this “one-probe-to-one-gene” cross-plat-
form mapping table, resulting in 8,550 “common”
genes that are probed by all six microarray platforms
(including the five microarray platforms used in
MAQC project in 2005 and the U133A platform used
in the current study). Among the 8,550 common
genes, 813 were also assayed with TaqMan® and were
used for comparing microarrays with TaqMan® assays.
Computational tools for data analysis
The microarray data generated in 2009 and the data
from the MAQC project generated in 2005 were
imported to ArrayTrack™ 3.5.0 [21], a software system
developed by the US Food and Drug Administration’s
National Center for Toxicological Research for microar-
ray data management, analysis, visualization, and inter-
pretation (http://www.fda.gov/ScienceResearch/
BioinformaticsTools/Arraytrack/). Unless stated other-
wise, the probe level data were summarized into probe-
set level data using RMA [17] before statistical testing;
these calculations were performed within ArrayTrack
that has an interface with Bioconductor 2.4. Note that
RMA summarization was performed separately on the 6
unexpired U133Plus2 microarrays and on the 6 expired
U133A microarrays hybridized in 2009. Data collected
by the MAQC project in 2005 were treated similarly,
with RMA summarization performed on the 6 microar-
rays (3 replicates per sample) from each platform.
The scaling factor of each microarray was calculated
with the Affy package in Bioconductor 2.4 within R 2.9.
The comparisons of log2 intensities, log2 fold changes,
and the POGs were conducted within MATLAB (Math-
Works, Natick, MA) and the corresponding homemade
source codes for these analyses are available upon
request.
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ized into probeset expression values with MAS5, a
trimmed mean of the normalized data is scaled to a
default value (e.g., 500 in the Affy package in Biocon-
ductor 2.4) by using a scaling factor [22]. The value of
the scaling factor is often used as a metric to assess the
quality of hybridization and the consistency across mul-
tiple microarrays. A scaling factor closer to 1 represents
better hybridization signal quality.
Statistical methods for identifying DEGs
Welch’s t-test is one of the common statistical methods
for gene selection. The p-value calculated by Welch’s t-
test is usually used to measure the statistical significance
of a gene differentially expressed in the two groups of
samples being compared. In our study, the p-value is
directly used for gene filtering without multiple-testing
correction. A gene was considered as significantly differ-
entially expressed if its p-value was less than 0.05.
T h ef o l dc h a n g e( F C )o fg e n ee x p r e s s i o ni n t e n s i t i e s
represents to what extent a gene is differentially
expressed between two groups of samples. After filtering
genes with a p ≥ 0.05 criterion, the remaining genes
were ranked by their fold changes (reference sample B/
reference sample A). Then, at each given cutoff a list of
the number of genes considered to be differentially
expressed genes was generated for subsequent
comparisons.
Percentage of overlapping genes (POG)
The genes contained in the two compared DEG lists
with the same direction of regulation (i.e., decreased or
increased) were considered to be overlapped genes. The
percentage of the overlapping genes (POG) [14,15,23]
among the total number of genes in one DEG list was
calculated and used to measure the consistency between
the two DEG lists by using the following equation:
POG
DD UU
L
=
+
×
×
2
100%,
where DD and UU are, respectively, the number of
commonly down- and up-regulated genes. L is the num-
ber of genes with down- or up-regulation. Similar to
previous studies [14,15,23] we selected an equal number
of down- and up-regulated genes in each of the two
D E G sl i s t s .T oo b t a i na no v e r a l lp i c t u r eo nt h eo v e r l a p
between two experiments, we evaluated the POG at a
wide range of gene selection criteria by changing L from
one (corresponding to the largest FC) to the lower num-
ber of genes in the two regulation directions (corre-
sponding to the smallest FC) with a step of one. See
Figures 5 and 6 for more information.
All microarray data specifically generated for this
study are available through the National Center for Bio-
technology Information’sG e n eE x p r e s s i o nO m n i b u s
(series accession number: GSE23906).
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